| NCT Number | NCT07223034 |
| Lead Sponsor | Memorial Sloan Kettering Cancer Center
Collaborators: Novartis Pharmaceuticals |
| Conditions | Glioma, Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4), Glioblastoma, IDH-wildtype, Diffuse Midline Glioma, H3 K27-Altered, Diffuse Hemispheric Glioma, H3 G34-mutant, Diffuse Pediatric-type High-grade Glioma, H3-wildtype and IDH-wildtype |
| Enrollment | 20 participants |
| Start Date | 2025-10-27 |
| Primary Completion | 2027-10 (estimated) |
| Study Completion | 2027-10 (estimated) |
| Updated on ClinicalTrials.gov | 2026-06-04 |